Member Info for inanaco

You are not the market ..... you are Ruck Rover

have a good day

The Market valued the Cash raise last year at 12p ....

now it see's the potential at 7p .. the only change I can see to the negative is

3 month delay to SCIB1

and scaling up the modi1 manufacturing . which as Lindy said is now sorted ...

so those two events have written off the Mcap MORE than the cash raise ... ?

why ?

all you are doing is Highlighting ... Yourself as the Ventriloquist with Tosh as your dummy ...

Have a good day, but devoting time to Drama Queens, really has no interest for me ..

notice the word Commence

Yet the Drama students think, that this means fully completed

which is why .... always check the facts rather than listen to "experts"

this is from the cash raising statement

The net proceeds from the Capital Raise, in addition to the Company's existing cash resources and anticipated tax credits, will be used to:

Â

·    Commence the SCIB1-checkpoint inhibitor Phase 2 US combination study in late stage melanoma, planned to start in Q4 2018 (subject to FDA approval) utilising the Ichor TriGrid v2.0 electroporation device;

·    Support the Cancer Research UK ("CRUK") development of SCIB2 for non-small-cell lung cancer ("NSCLC");

·    Commence the First-In-Human study with Modi-1 in patients with triple-negative breast cancer ("TNBC"), ovarian cancer and sarcoma planned to start in H1 2019;

·    Identify Modi-specific T cell receptors in collaboration with BioNTech; and

·    Initiate pre-clinical Modi-2 development programme for oesophageal, gastric, pancreatic and colorectal cancers

we are ok for cash

Imprisonment is not normally included in a job description ...

The problem is that cash flow, funding etc is very important if you are raising cash on the market but the market causes a double movement ..

so you """"assume"""" the price of the next cash raise is 6p say... the market moves to 6p causing a raise at 5p

but currently the market ignores the outcome of funding ... its pricing nothing in ... yet the indications given by scancell suggest that it should.

Douve87

the problem with concentrating in only one area, you would have missed Homocitrulline patents and the associated work and expenditure to prove them up ..

this is the problem we are at the top of the game in a patent land grab in Autophagy .. why give others the chance to plant the flag ?

the money is not relevant .. because the flip side is a massive pipeline ..

which is why its called a balance sheet ....

so the issue is Scancell is raising funds which identifies the expenditure ... the market is putting up the cash but then ignoring the result ?

Chester
Nothing in the RNS to be alarmed about at all as two events are not repeated, Manufacture of modi-1 and Ichor

what should be highlighted is

Pre-clinical development underway with Modi-2, including progress made in the characterisation of specific homocitrullinated peptides for clinical development

so that vaccine is based on the new Patent applied for .. so now they are assembling the vaccine .. again a one off development cost

the issue is the Share price does not relate to the Pipeline ..

so much effort is made by the few to explain that spending money on identifiable research is bad ... and that all this development work can be done by feeding peanuts to monkeys

what's important about the moditope trial is NOT that we can't afford to complete it, its that its split into two then into three so the full cost of that trial is unknown because of the size of it

however we are only treating 9 patients in the phase 1 so the efficacy will be assessed before we expand the trial giving shareholders the inside track on just how good moditope is again the target group is late stage cancer and patients on the phase 1 are late stage cancer patients.

Scancell has still to announce the results of the Collaboration between BioNtech and Scancell ..

indeed this area will be subject to expansion as the identified Homocitrulline epitopes are added.

anyway the usual screams of doom from those dedicated to wrecking our investments is usual ... however the amount sold is tiny / relative to the share price movement

Nothing to dramatise ......... but Ruck Tommy and Knowlesi should really be at the London Palladium

who took the call ...

don;t know ... but i have

observational bias

Information Bias ...

lack of correctional shoes i believe

I don't pick up on 666 calls

page 33

https://www.calculuscapital.com/cms/media/Scancell-Cap-mkts_all.pdf

again ....... what then appears ?

IFN

Interferon Gamma ....

that stresses Cancer ....... tick tock

all the science supports Scancell ..

Now you can see why Scancell delayed Modi1 ........... and added the very complex adjuvant

""""" Although the mechanisms regulating development of various CD4+ Th subsets have been clarified in terms of the cytokine and transcription factor requirement, the CD4 CTL differentiation mechanism remains elusive. These cells are thought to be most closely related to Th1 cells secreting IFN? """"""""""

Scancell has achieved the Cytotoxic CD4 T cell Th1 ............

, influenza-specific cytotoxic activity of CD8 CTLs is impaired in the chronic phase of infection, and CD4 CTLs can function instead

its the acute stages .... that you might see the rare CD4 ,,,,,,,,

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321676/

Abstract
CD4+ T cells with cytotoxic activity (CD4 CTL) have been observed in various immune responses. These cells are characterized by their ability to secrete granzyme B and perforin and to kill the target cells in an MHC class II-restricted fashion. Although CD4 CTLs were once thought to be an in vitro artifact associated with long-term culturing, they have since been identified in vivo and shown to play important roles in antiviral and antitumor immunity, as well as in inflammation. Functional characterization of CD4 CTL suggests their potential significance for therapeutic purposes. However, in order to develop effective CD4 CTL therapy it is necessary to understand the differentiation and generation of these cells. Although the mechanisms regulating development of various CD4+ Th subsets have been clarified in terms of the cytokine and transcription factor requirement, the CD4 CTL differentiation mechanism remains elusive. These cells are thought to be most closely related to Th1 cells secreting IFN? and regulated by eomesodermin and/or T-bet transcription factors for their differentiation. However, our studies and those of others have identified CD4 CTLs within other CD4+ T cell subsets, including naïve T cells. We have identified class I-restricted T cell-associated molecule as a marker of CD4 CTL and, by using this marker, we detected a subset of naïve T cells that have the potential to differentiate into CD4 CTL. CD4 CTL develops at sites of infections as well as inflammation. In this review, we summarize recent findings about the generation of CD4 CTL and propose a model with several differentiation pathways.

Glad you are not negotiating ... Would End up with a Zoo ....

Probably done in Euro as its Eurozone based ...